TABLE 3.
Ongoing clinical trials targeting ovarian cancer tumor microenvironment (TME).
| Drug | Combination therapy | Simple size | Status | Trial number | Phase |
| Target VEGF | |||||
| Sevacizumab | Paclitaxel; Topotencan | 48 | Recruiting | NCT03763123 | 1 |
| Bevacizumab | Paclitaxel; Ricolinostat | 6 | Terminated | NCT02661815 | 1 |
| Bevacizumab | Carboplatin; Paclitaxel | 9 | Completed | NCT01219777 | 1 |
| Bevacizumab | Niraparib | 108 | Active, not recruiting | NCT02354131 | 1,2 |
| Bevacizumab | Carboplatin; Paclitaxel; Rucaparib | 234 | Recruiting | NCT03462212 | 1,2 |
| Bevacizumab | – | 27 | Unknown | NCT02022917 | 2 |
| Bevacizumab | – | 35 | Recruiting | NCT02884648 | 2 |
| Bevacizumab | – | 36 | Completed | NCT00748657 | 2 |
| Bevacizumab | – | 40 | Not yet recruiting | NCT03611179 | 2 |
| Bevacizumab | – | 64 | Completed | NCT00022659 | 2 |
| Bevacizumab | Gemcitabine; Carboplatin; Cisplatin; Oxaliplatin | 7 | Terminated | NCT01936974 | 2 |
| Bevacizumab | Paclitaxel; Cisplatin | 20 | Completed | NCT00511992 | 2 |
| Bevacizumab | Irinotecan | 29 | Completed | NCT01091259 | 2 |
| Bevacizumab | Topotecan | 40 | Completed | NCT00343044 | 2 |
| Bevacizumab | Gemcitabine; Carboplatin | 45 | Completed | NCT00267696 | 2 |
| Bevacizumab | RAD001 | 50 | Completed | NCT01031381 | 2 |
| Bevacizumab | Tocotrienol | 60 | Recruiting | NCT04175470 | 2 |
| Bevacizumab | Erlotinib; Paclitaxel; Carboplatin | 60 | Completed | NCT00520013 | 2 |
| Bevacizumab | Paclitaxel; Carboplatin | 62 | Completed | NCT00129727 | 2 |
| Bevacizumab | Anetumab Ravtansine; paclitaxel | 96 | Recruiting | NCT03587311 | 2 |
| Bevacizumab | Niraparib | 106 | Active, not recruiting | NCT03326193 | 2 |
| Bevacizumab | Fosbretabulin Tromethamine | 107 | Completed | NCT01305213 | 2 |
| Bevacizumab | Everolimus | 150 | Unknown | NCT00886691 | 2 |
| Bevacizumab | Paclitaxel; Carboplatin | 190 | Completed | NCT00937560 | 2 |
| Bevacizumab | Temsirolimus | 252 | Completed | NCT01010126 | 2 |
| Bevacizumab | Cyclophosphamide | 20 | Completed | NCT00856180 | 3 |
| Bevacizumab | Capecitabine; Carboplatin; Oxaliplatin; Paclitaxel | 50 | Active, not recruiting | NCT01081262 | 3 |
| Bevacizumab | Carboplatin; Paclitaxel | 100 | Active, not recruiting | NCT03635489 | 3 |
| Bevacizumab | Rucaparib | 190 | Not yet recruiting | NCT04227522 | 3 |
| Bevacizumab | Paclitaxel; Carboplatin; PLD; Gemcitabine | 406 | Unknown | NCT01802749 | 3 |
| Bevacizumab | Carboplatin; Paclitaxel | 1021 | Completed | NCT01239732 | 3 |
| Bevacizumab | Paclitaxel; Carboplatin | 400 | Unknown | NCT01706120 | 4 |
| Target VEGFR | |||||
| Apatinib | Fluzoparib | 98 | Active, not recruiting | NCT03075462 | 1 |
| Chiauranib | – | 25 | Completed | NCT03166891 | 1,2 |
| BIBF 1120 | – | 32 | Completed | NCT01669798 | 2 |
| JI-101 | – | 31 | Active, not recruiting | NCT01853644 | 2 |
| Regorafenib | – | 43 | Recruiting | NCT02736305 | 2 |
| Tivozanib | – | 31 | Active, not recruiting | NCT01853644 | 2 |
| Apatinib | Albumin-bound paclitaxel | 35 | Not yet recruiting | NCT03942068 | 2 |
| Apatinib | PLD | 150 | Recruiting | NCT04348032 | 2 |
| Cediranib | Olaparib | 4 | Completed | NCT02340611 | 2 |
| Pazopanib | Paclitaxel | 118 | Active, not recruiting | NCT02383251 | 2 |
| Regorafenib | Tamoxifen | 68 | Active, not recruiting | NCT02584465 | 2 |
| Cediranib | Laparib; Paclitaxel; Pegylated Liposomal Doxorubicin Hydrochloride; Topotecan | 680 | Recruiting | NCT02502266 | 2,3 |
| Cediranib | Olaparib | 618 | Recruiting | NCT03278717 | 3 |
| Target CTLA-4 | |||||
| Tremelimumab | Olaparib | 50 | Recruiting | NCT02571725 | 1,2 |
| Tremelimumab | Olaparib | 170 | Recruiting | NCT04034927 | 2 |
| Target PD-1 | |||||
| ABBV-181 | SC-003 | 74 | Terminated | NCT02539719 | 1 |
| PDR001 | Ribociclib; Fulvestrant | 60 | Recruiting | NCT03294694 | 1 |
| Nivolumab | COM701 | 140 | Recruiting | NCT03667716 | 1 |
| Pembrolizumab | Modified Vaccinia Virus Ankara Vaccine Expressing p53 | 28 | Recruiting | NCT03113487 | 1 |
| Pembrolizumab | AMG386 | 60 | Active, not recruiting | NCT03239145 | 1 |
| Nivolumab | Varlilumab | 175 | Completed | NCT02335918 | 1,2 |
| Pembrolizumab | Carboplatin | 29 | Active, not recruiting | NCT03029598 | 1,2 |
| Pembrolizumab | PLX3397 | 78 | Terminated | NCT02452424 | 1,2 |
| Pembrolizumab | Galinpepimut-S | 90 | Recruiting | NCT03761914 | 1,2 |
| Pembrolizumab | Niraparib | 122 | Active, not recruiting | NCT02657889 | 1,2 |
| Pembrolizumab | ENB003 | 130 | Not yet recruiting | NCT04205227 | 1,2 |
| Sintilimab | Manganese Chloride; nab-paclitaxel; Platinum chemotherapy | 80 | Recruiting | NCT03989336 | 1,2 |
| TSR042 | Niraparib | 150 | Recruiting | NCT03955471 | 2 |
| Nivolumab | Rucaparib | 1 | Active, not recruiting | NCT03824704 | 2 |
| Pembrolizumab | – | 100 | Active, not recruiting | NCT02644369 | 2 |
| Pembrolizumab | – | 376 | Active, not recruiting | NCT02674061 | 2 |
| Pembrolizumab | Gemcitabine; Cisplatin | 21 | Active, not recruiting | NCT02608684 | 2 |
| Pembrolizumab | Carboplatin | 22 | Not yet recruiting | NCT04387227 | 2 |
| Pembrolizumab | Carboplatin; Paclitaxel | 30 | Recruiting | NCT02766582 | 2 |
| Pembrolizumab | DPX-Survivac; Cyclophosphamide | 42 | Recruiting | NCT03029403 | 2 |
| Pembrolizumab | DPX-Survivac; Cyclophosphamide | 184 | Recruiting | NCT03836352 | 2 |
| SHR-1210 | Famitinib | 265 | Recruiting | NCT03827837 | 2 |
| Nivolumab | TSR-042; Chemotherapy Drugs | 196 | Not yet recruiting | NCT03651206 | 2,3 |
| Nivolumab | Rucaparib | 1012 | Recruiting | NCT03522246 | 3 |
| TSR-042 | Niraparib | 1228 | Recruiting | NCT03602859 | 3 |
| Target PD-L1 | |||||
| Atezolizumab | Carbplatin, Cyclophophamide | 12 | Active, not recruiting | NCT02914470 | 1 |
| Atezolizumab | RO6870810 | 36 | Terminated | NCT03292172 | 1 |
| Atezolizumab | Carboplatin; Paclitaxel; Niraparib; Gemcitabine; PLD | 414 | Recruiting | NCT03598270 | 1 |
| MEDI4736 | Eribulin | 9 | Active, not recruiting | NCT03430518 | 1 |
| MEDI4736 | Focal radiotherapy | 22 | Recruiting | NCT03283943 | 1 |
| Atezolizumab | DEC-205/NY-ESO-1 Fusion Protein CDX-1401; Guadecitabine; Poly ICLC | 75 | Suspended | NCT03206047 | 1,2 |
| Avelumab | Entinostat | 140 | Active, not recruiting | NCT02915523 | 1,2 |
| MEDI4736 | PLD; Motolimod; | 53 | Active, not recruiting | NCT02431559 | 1,2 |
| MEDI4736 | ONCOS-102 | 78 | Recruiting | NCT02963831 | 1,2 |
| TQB2450 | Anlotinib | 30 | Not yet recruiting | NCT04236362 | 1,2 |
| Atezolizumab | Vigil | 25 | Active, not recruiting | NCT03073525 | 2 |
| Avelumab | – | 5 | Terminated | NCT03312114 | 2 |
| MEDI4736 | Azacitidine | 28 | Active, not recruiting | NCT02811497 | 2 |
| MEDI4736 | TPIV200 | 29 | Active, not recruiting | NCT02764333 | 2 |
| Atezolizumab | Carboplatin; Paclitaxel; Niraparib; Gemcitabine; PLD | 414 | Recruiting | NCT03598270 | 3 |
| Avelumab | PLD | 566 | Active, not recruiting | NCT02580058 | 3 |
| Target VEGF combined with VEGFR | |||||
| Bevacizumab | BIBF 1120 | 21 | Completed | NCT02835833 | 1 |
| Bevacizumab | Sorafenib | 55 | Completed | NCT00436215 | 2 |
| Target VEGF combined with PD-1 | |||||
| Bevacizumab | Pembrolizumab | 40 | Not yet recruiting | NCT03596281 | 1 |
| Bevacizumab | TSR042; Niraparib | 40 | Active, not recruiting | NCT03574779 | 2 |
| Bevacizumab | Pembrolizumab; Cyclophosphamide | 40 | Active, not recruiting | NCT02853318 | 2 |
| Bevacizumab | Pembrolizumab; Olaparib | 44 | Not yet recruiting | NCT04361370 | 2 |
| Bevacizumab | Pembrolizumab; Carboplatin; Paclitaxel | 45 | Not yet recruiting | NCT03275506 | 2 |
| Bevacizumab | Nivolumab; Rucaparib | 76 | Recruiting | NCT02873962 | 2 |
| Bevacizumab | Pembrolizumab; Carboplatin; Paclitaxel | 1086 | Recruiting | NCT03740165 | 3 |
| Bevacizumab | TSR042; Niraparib; Carboplatin; Paclitaxel | 337 | Not yet recruiting | NCT03806049 | 3 |
| Target VEGF combined with PD-L1 | |||||
| Bevacizumab | MEDI4736; Olaparib | 427 | Active, not recruiting | NCT02734004 | 1,2 |
| Bevacizumab | Atezolizumab; Carboplatin; Paclitaxel | 40 | Recruiting | NCT03394885 | 1,2 |
| Bevacizumab | Avelumab; M6620; Carboplatin; Paclitaxel; Gemcitabine; PLD | 3 | Completed | NCT03704467 | 2 |
| Bevacizumab | Atezolizumab; Cobimetinib | 29 | Recruiting | NCT03363867 | 2 |
| Bevacizumab | MEDI4736; Olaparib | 74 | Active, not recruiting | NCT04015739 | 2 |
| Bevacizumab | Atezolizumab; Acetylsalicylic acid | 160 | Recruiting | NCT02659384 | 2 |
| Bevacizumab | Atezolizumab; Pegylated Liposomal Doxorubicin Hydrochloride | 488 | Suspended | NCT02839707 | 2,3 |
| Bevacizumab | Avelumab; Chemotherapy | 79 | Active, not recruiting | NCT03642132 | 3 |
| Bevacizumab | Atezolizumab; Platinum-based chemotherapy | 614 | Active, not recruiting | NCT02891824 | 3 |
| Bevacizumab | Atezolizumab; Chemotherapy | 664 | Recruiting | NCT03353831 | 3 |
| Bevacizumab | MEDI4736; Olaparib; Carboplatin; Paclitaxel | 1056 | Recruiting | NCT03737643 | 3 |
| Bevacizumab | Atezolizumab; Paclitaxel; Carboplatin | 1300 | Active, not recruiting | NCT03038100 | 3 |
| Target VEGFR combined with PD-1 | |||||
| Apatinib | SHR-1210 | 28 | Not yet recruiting | NCT04068974 | 1 |
| Lenvatinib | Pembrolizumab | 180 | Active, not recruiting | NCT03797326 | 2 |
| Target Angs combined with PD-1 | |||||
| AMG386 | Pembrolizumab | 60 | Active, not recruiting | NCT03239145 | 1 |
| Target Angs combined with VEGF | |||||
| MEDI3617 | Bevacizumab; Paclitaxel; Carboplatin | 162 | Completed | NCT01248949 | 1 |
| Target CTLA-4 combined with PD-1 | |||||
| Ipilimumab | Nivolumab | 48 | Recruiting | NCT03508570 | 1 |
| Ipilimumab | Nivolumab | 5 | Terminated | NCT03342417 | 2 |
| Ipilimumab | Nivolumab | 62 | Recruiting | NCT03355976 | 2 |
| Tremelimumab | Nivolumab | 100 | Active, not recruiting | NCT02498600 | 2 |
| Target CTLA-4 combined with PD-L1 | |||||
| Tremelimumab | MEDI4736; Chemotherapy | 61 | Recruiting | NCT03249142 | 1,2 |
| Tremelimumab | Olaparib; MEDI4736 | 36 | Recruiting | NCT02953457 | 2 |
| Tremelimumab | MEDI4736 | 100 | Recruiting | NCT03026062 | 2 |
PLD, pegylated liposomal doxorubicin.